Gynaecomastia — the benign enlargement of glandular breast tissue in males — is far more common than most people appreciate. Estimates suggest it affects between 32% and 65% of men at some point in their lifetime, making it the most frequently encountered condition of the male breast. It occurs across all age groups, from newborns to older men, and is often physiological rather than pathological. Despite its prevalence, many men delay seeking advice due to embarrassment. This article explains how common gynaecomastia is, what causes it, when to see a GP, and what assessment and treatment options are available on the NHS.

How Common Is Gynaecomastia in the UK

Gynaecomastia affects an estimated 32–65% of men at some point in their lifetime and is the most common condition of the male breast seen in UK primary and secondary care.

Gynaecomastia — the benign enlargement of glandular breast tissue in males — is considerably more common than many people realise. Estimates suggest it affects between 32% and 65% of men at some point during their lifetime, making it the most frequently encountered condition of the male breast. Prevalence varies significantly depending on the age group studied and the diagnostic criteria used, which partly explains the wide range reported across clinical literature (NICE CKS: Gynaecomastia; BMJ Best Practice).

In the UK, gynaecomastia is commonly seen in breast and endocrinology clinics and accounts for a notable proportion of GP consultations related to male breast concerns. The NHS website and NICE CKS identify it as one of the leading causes of male breast symptoms presenting in both primary and secondary care. Despite its frequency, many men delay seeking advice due to embarrassment or uncertainty about whether their symptoms warrant medical attention.

The condition is not confined to any single demographic. It occurs across all ethnicities and body types, though it is more prevalent at certain life stages — particularly in newborns, adolescents, and older men. In many cases, gynaecomastia is physiological (a normal response to hormonal fluctuations) rather than pathological, and it resolves without intervention. Understanding how common it is can help reduce stigma and encourage men to seek timely, appropriate assessment.

What Causes Gynaecomastia at Different Life Stages

Gynaecomastia is caused by an oestrogen-to-androgen imbalance; triggers vary by age and include transplacental oestrogens in neonates, pubertal hormonal shifts in adolescents, and medications or hypogonadism in adults.

Gynaecomastia arises from an imbalance between oestrogen and androgen activity in breast tissue. Even in males, small amounts of oestrogen are produced, and when the ratio of oestrogen to testosterone rises — whether due to increased oestrogen, reduced testosterone, or altered receptor sensitivity — glandular breast tissue can proliferate. This hormonal mechanism underpins gynaecomastia across all age groups, though the specific triggers differ.

In neonates, transplacental transfer of maternal oestrogens causes transient breast enlargement in up to 90% of newborn males. This typically resolves within a few weeks and requires no treatment.

In adolescents, gynaecomastia is extremely common, affecting an estimated 50–70% of boys during puberty. The temporary surge in oestradiol relative to testosterone during early puberty is responsible. In most cases, the condition resolves spontaneously within 6 to 24 months. Persistent pubertal gynaecomastia beyond two years warrants further evaluation.

In adult and older men, the causes are more varied and may include:

• Medications — a significant and often overlooked contributor; commonly implicated drugs in UK practice include spironolactone, cimetidine, anti-androgens (e.g., bicalutamide), 5-alpha-reductase inhibitors (e.g., finasteride, dutasteride), GnRH analogues, anabolic steroids, some antipsychotics, certain antihypertensives, antiretrovirals (e.g., efavirenz), ketoconazole, and digoxin. This is not an exhaustive list — always review the full medication history

• Hypogonadism — primary or secondary reduction in testosterone production, including that caused by Klinefelter syndrome (47,XXY), which is associated with small testes, primary hypogonadism, and an increased risk of male breast cancer

• Liver disease or cirrhosis — impairing oestrogen metabolism

• Hyperthyroidism or chronic kidney disease

• Obesity — adipose tissue converts androgens to oestrogens via aromatisation

• Recreational drug use — alcohol and opioids have been implicated; an association with cannabis has been suggested but the evidence is limited and inconsistent, and this link should be interpreted with caution

In approximately 25% of cases, no identifiable cause is found, and the condition is classified as idiopathic. A thorough medication review is always an essential first step in assessment (NICE CKS: Gynaecomastia).

When to See a GP About Breast Tissue Changes

Any new or unexplained male breast change warrants GP assessment; NICE NG12 recommends urgent two-week-wait referral for men aged 30 and over with an unexplained breast lump.

Many men are unsure whether breast changes warrant a GP visit, particularly when symptoms appear mild or develop gradually. As a general principle, any new or unexplained breast change in a male should be assessed by a clinician, even if the most likely explanation is benign gynaecomastia. Early assessment helps exclude rarer but more serious conditions, including male breast cancer, which — whilst uncommon — accounts for approximately 1% of all breast cancer diagnoses in the UK (Cancer Research UK).

You should contact your GP promptly if you notice:

• A firm, rubbery lump beneath one or both nipples

• Unilateral (one-sided) breast swelling that is hard, irregular, or fixed

• Nipple discharge, particularly if bloodstained

• Skin changes over the breast, such as dimpling, puckering, or ulceration

• Breast pain or tenderness that is persistent or worsening

• Axillary (armpit) lymph node swelling

• Swelling accompanied by testicular changes, unexplained weight loss, or fatigue

In line with NICE NG12 (Suspected Cancer: Recognition and Referral), GPs should consider an urgent two-week-wait (2WW) referral for men aged 30 and over with an unexplained breast lump. For men aged 50 and over, unilateral nipple changes — including discharge, retraction, or other concerning features — also warrant urgent referral. For men under 30 with an unexplained lump, a non-urgent referral for specialist assessment is appropriate. These thresholds apply to all people, including males.

Adolescents with gynaecomastia that has persisted beyond two years, or that is causing significant psychological distress, should also be referred for specialist review. Similarly, men who have recently started a new medication and notice breast changes should inform their prescribing clinician, as a drug-related cause may be readily addressable.

It is worth noting that pseudogynaecomastia — fatty enlargement of the breast without true glandular proliferation, common in overweight men — does not carry the same clinical implications, though it can be difficult to distinguish from true gynaecomastia without examination. A GP can help differentiate between the two and advise accordingly.

How Gynaecomastia Is Diagnosed and Assessed

Diagnosis involves clinical history, physical examination, and first-line blood tests including testosterone, LH, FSH, oestradiol, hCG, liver and renal function, TFTs, and prolactin.

Diagnosis begins with a thorough clinical history and physical examination. The GP or specialist will assess the onset and duration of symptoms, any associated medications or recreational drug use, and relevant medical history including liver, kidney, or thyroid conditions. On examination, true gynaecomastia typically presents as a firm, disc-like mound of tissue centred beneath the nipple-areolar complex, distinguishable from the softer, diffuse fatty tissue of pseudogynaecomastia.

First-line investigations, guided by history and examination and broadly in line with NICE CKS guidance, typically include:

• Serum testosterone, LH, and FSH — to assess gonadal function

• Oestradiol and hCG (human chorionic gonadotrophin) — elevated hCG may suggest a testicular or extragonadal germ cell tumour; when a germ cell tumour is suspected, alpha-fetoprotein (AFP) should also be measured alongside hCG

• Liver function tests and renal function

• Thyroid function tests (TFTs)

• Prolactin — to exclude hyperprolactinaemia

• Sex hormone-binding globulin (SHBG) and calculated free testosterone may be helpful in selected cases

Where Klinefelter syndrome is suspected (e.g., small testes, primary hypogonadism, tall stature), a karyotype should be arranged, as this condition carries an elevated risk of male breast cancer and has specific management implications.

If a testicular tumour is suspected, scrotal ultrasound should be arranged urgently. Breast imaging — typically ultrasound in younger men or mammography in older men — may be requested when the clinical picture is uncertain or when features raise concern for malignancy. In breast clinics, a triple assessment approach (clinical examination, imaging, and biopsy where indicated) is standard practice for evaluating breast lesions. NICE NG12 supports a two-week-wait urgent referral for suspected breast cancer in males presenting with hard, irregular, or unilateral breast masses (see 'When to See a GP' above for age-based criteria).

In adolescents with typical pubertal gynaecomastia and no red flag features, investigation may not be immediately necessary, and a period of watchful waiting with reassurance is often appropriate. However, if the condition persists or is atypical, referral to a paediatric endocrinologist should be considered.

Treatment and Management Options Available on the NHS

Management ranges from watchful waiting and treating underlying causes to off-label pharmacological therapy (e.g., tamoxifen) in specialist settings; surgical treatment is definitive but not routinely NHS-funded.

The management of gynaecomastia depends on its underlying cause, duration, severity, and the degree of distress it causes. For many men — particularly adolescents with physiological gynaecomastia — reassurance and watchful waiting are the most appropriate initial approach, given the high rate of spontaneous resolution. Addressing any identifiable underlying cause, such as stopping or switching a causative medication or treating an underlying endocrine disorder, can also lead to regression of breast tissue, particularly in early-stage cases.

Pharmacological treatment is not routinely prescribed for gynaecomastia in UK primary care, but off-label options may be considered by specialists on a case-by-case basis, particularly when the condition is of recent onset (typically within 12 months) and is causing significant pain or distress. Medical therapy is generally less effective once the glandular tissue has become fibrotic, which tends to occur after approximately 12 months. Options used in specialist settings include:

• Tamoxifen (an oestrogen receptor antagonist) — used off-licence; this has the best available (though still limited) evidence for reducing breast volume and tenderness in recent-onset, painful gynaecomastia

• Raloxifene — another selective oestrogen receptor modulator (SERM) with some evidence of benefit from small studies, though evidence is more limited than for tamoxifen

• Aromatase inhibitors (e.g., anastrozole) — occasionally considered in specialist settings for adolescents with persistent pubertal gynaecomastia, but evidence is weak and routine use is not generally recommended

All of these agents are used off-label for gynaecomastia and are not licensed for this indication in the UK. Patients should be counselled about potential adverse effects before starting treatment; for example, tamoxifen and raloxifene carry risks including thromboembolic events and, with long-term use, endometrial changes. Aromatase inhibitors may affect bone density. Patients who experience suspected side effects from any medicine should report them via the MHRA Yellow Card Scheme (available at yellowcard.mhra.gov.uk). Prescribers should refer to the relevant MHRA/EMC Summary of Product Characteristics (SmPC) and BNF monograph for full prescribing information.

Experiencing these side effects? Our pharmacists can help you navigate them →

Surgical management — most commonly subcutaneous mastectomy or liposuction-assisted techniques — is the definitive treatment for persistent or severe gynaecomastia. However, this is generally not routinely funded by the NHS and is subject to local eligibility criteria. NHS England's Evidence-Based Interventions (EBI) programme identifies gynaecomastia surgery as a procedure that should only be commissioned where specific clinical criteria are met, and policies vary across Integrated Care Boards (ICBs). Patients seeking surgery on the NHS should discuss eligibility with their GP and specialist team. Private surgical options are available for those who do not meet NHS thresholds but wish to pursue treatment.

For further information, patients can refer to the NHS website (Enlarged male breasts — gynaecomastia), NICE CKS: Gynaecomastia, and the Society for Endocrinology patient information resources.

Frequently Asked Questions